Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Suberoylanilide Hydroxamic Acid (NSC-701852) for Recurrent or Primary Refractory Hodgkin's Lymphoma

NCT00132028 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00132028
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00132028 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Suberoylanilide Hydroxamic Acid (NSC-701852) for Recurrent or Primary Refractory Hodgkin's Lymphoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2005
Completion date
May 31, 2009
Enrollment
27 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adult favorable prognosis hodgkin lymphoma, adult lymphocyte depletion hodgkin lymphoma, adult lymphocyte predominant hodgkin lymphoma, adult mixed cellularity hodgkin lymphoma, adult nodular lymphocyte predominant hodgkin lymphoma, adult nodular sclerosis hodgkin lymphoma, adult unfavorable prognosis hodgkin lymphoma, recurrent adult hodgkin lymphoma